指南与共识细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

志贺菌控制性人类感染模型共识报告:临床终点

Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints.
指南 / 共识 · Clin Infect Dis · 2019-01-01

该共识报告针对志贺菌控制性人类感染模型(CHIM)的临床终点进行标准化,专家工作组于2018年2月2日召开会议,基于现有CHIM研究数据,定义志贺菌病的主要终点为严重腹泻或中度腹泻或痢疾,后者需伴发热38.0°C和/或呕吐和/或至少中度全身/肠道症状,并建议使用盲法独立委员会裁定终点及早期抗生素使用标准。

要点

  • 主要终点定义为严重腹泻或中度腹泻或痢疾,后者需伴发热38.0°C和/或呕吐和/或至少中度全身/肠道症状。
  • 建议使用盲法独立委员会对每个受试者的主要终点进行裁定。
  • 早期抗生素使用标准:达到主要终点、发热≥39.0°C或研究医生认为合适时;否则感染挑战后120小时给药。

核心结论

  • 共识主要终点使志贺菌病表现为严重腹泻或中度腹泻或痢疾,后者需伴发热38.0°C和/或呕吐和/或至少中度全身/肠道症状。
  • 使用盲法独立委员会裁定主要终点被认为很重要。
  • 建立了早期抗生素使用标准:达到主要终点、发热≥39.0°C或研究医生认为合适时给药,否则感染挑战后120小时给药。

研究设计与样本

  • 专家工作组于2018年2月2日召开会议,审查迄今进行的志贺菌CHIM研究的临床数据并制定共识主要终点。
  • CHIM目前在美国3个中心进行,使用福氏志贺菌2a株2457T和宋内志贺菌53G株。

关键数值与推荐

  • 主要终点:严重腹泻或中度腹泻或痢疾;后两者需伴发热38.0°C和/或呕吐和/或至少中度全身/肠道症状。
  • 早期抗生素使用标准:(1)达到主要终点;(2)发热≥39.0°C;(3)研究医生认为合适;否则感染挑战后120小时给药。
  • 工作组同意需采集的客观和主观症状,并标准化评估受试者报告症状严重程度的方法。

临床怎么用

  • 在志贺菌CHIM研究中采用共识主要终点定义,并使用盲法独立委员会裁定终点。
  • 根据早期抗生素使用标准决定给药时机,以平衡志愿者安全与主要结局评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Shigella controlled human infection model (CHIM) is valuable for assessing candidate Shigella vaccine efficacy and potentially accelerating regulatory approval. The Shigella CHIM is currently being conducted at 3 sites in the United States using Shigella flexneri 2a strain 2457T and Shigella sonnei strain 53G. Shigellosis can present variably as watery diarrhea alone or with dysentery, and can be accompanied by manifestations including fever, abdominal cramps, tenesmus, and malaise. For comparability, it is important to harmonize the primary clinical endpoint. An expert working group was convened on 2 February 2018 to review clinical data from Shigella CHIM studies performed to date and to develop a consensus primary endpoint. The consensus endpoint enabled "shigellosis" to present as severe diarrhea or moderate diarrhea or dysentery. The latter 2 criteria are met when concurrent with fever of 38.0°C and/or vomiting, and/or a constitutional/enteric symptom graded at least as "moderate" severity. The use of a blinded independent committee to adjudicate the primary endpoint by subject was also regarded as important. As safety of volunteers in challenge studies is of paramount importance and treatment timing can affect primary outcomes, a standard for early antibiotic administration was established as follows: (1) when the primary endpoint is met; (2) if a fever of ≥39.0°C develops; or (3) if the study physician deems it appropriate. Otherwise, antibiotics are given at 120 hours postinfectious challenge. The working group agreed on objective and subjective symptoms to be solicited, and standardized methods for assessing subject-reported severity of symptoms.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. MacLennan CA, Riddle MS, Chen WH, et al. Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints. Clin Infect Dis. 2019. PMID: 31816065. doi:10.1093/cid/ciz891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。